Pharma
Linvesta-EMP (Linagliptin + Empagliflozin Tablets)
Combination DPP-4 inhibitor and SGLT2 inhibitor; 5 mg/25 mg Linagliptin/Empagliflozin tablets for Type 2 Diabetes.
Linvesta-EMP (Linagliptin + Empagliflozin Tablets)
Linvesta-EMP is a combination medication containing Linagliptin and Empagliflozin, used to improve blood sugar control in adults with type 2 diabetes mellitus. Linagliptin is a DPP-4 inhibitor that increases insulin release and decreases glucagon levels. Empagliflozin is an SGLT2 inhibitor that helps the kidneys remove glucose from the bloodstream through urine. This dual-action approach helps lower both fasting and post-meal blood glucose levels. It is typically prescribed as an adjunct to diet and exercise and may also reduce the risk of cardiovascular death in patients with established cardiovascular disease. Not for use in type 1 diabetes. Common side effects include urinary tract infections and upper respiratory tract infections.
You May Also Like
Antihypertensive and alpha-2 agonist; 0.1 mg tablets for blood pressure and ADHD management.
Combination antidiabetic agent; 2.5 mg Linagliptin and 1000 mg Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/850 mg Sitagliptin/Metformin tablets for Type 2 Diabetes.
High-strength immunosuppressant; 100 mg Cyclosporine soft gelatin capsules for transplant maintenance.